HK Stock Market Move | GENFLEET-B(02595) rises nearly 4% in the afternoon; oral KRAS G12D inhibitor discloses excellent clinical data

GENFLEET-B(02595) rose nearly 4% in the afternoon. As of press time, it was up 3.57% at HK$30.76, with a turnover of HK$93.7925 million. On the news front, GenFleet Therapeutics/Verastem Oncology recently disclosed that the oral KRAS G12D inhibitor GFH375/VS-7375 has achieved positive progress in multiple domestic and overseas clinical studies, and released the latest data from the relevant studies, demonstrating good efficacy and safety. China Securities Co.,Ltd. stated in a research report that, based on the advancement of the registrational Phase III study of GFH375 and the expansion into multiple indications and frontline combination therapies, coupled with the clinical potential of GFH276, the pipeline layout of GFS202A and GFS784, as well as the progress of overseas development and cooperation, the clinical and commercial prospects of the company's core products are expected to become clear, providing support for medium- to long-term development.